Azienda Socio Sanitaria Territoriale Dei Sette Laghi — Clinical Trial Site

72 Registered trials

41 Currently recruiting

Organisation

Azienda Socio Sanitaria Territoriale Dei Sette Laghi

Location

Varese, Italy

Identifier

ORG-100043719

Address

Viale Luigi Borri N 57, 21100, Italy

Departments

#2832: Struttura Complessa Medicina Genarale
Anestesia e Terapia intesiva
AO Ospedale di Circolo e Fondazione Macchi
ASSL Sette Laghi - Ospedale Tradate
Complex Structure of Hematology
Department of Emergency and Thrombosis and Hemostasis clinic
Dipar&mento di Ematologia
Dipartimento di Emergenza e Urgenza
DIPARTIMENTO DI MEDICINA SPECIALISTICA
Dipartimento Emergenza
dipartimento ginecologia e ostreticia
Dipartimento Materno Infantile
Division of Hematology
DIVISIONE DI EMATOLOGIA
Ematologia
Endocrinology
General Medicine
Ginecology
Gynecological Obstetrics Department
Haematology Department
Hematology
Hematology Trial Unit
IT052A: Unità Operativa Complessa di Ematologia
Medical Area Department
Medical oncology
Medicina Interna
N/A
ONCOEMATOLOGIA
Oncologia
Oncologia Medica
Oncology
Ospedale di Circolo e Fondazione Macchi -SC Ematologia
Ospedale di Circolo e Fondazione Macchi, SC Ematologia
Ospedale Galmarini di Tradate
Pediatria
Pediatria Ospedale Filippo del Ponte
Presidio Ospedale di Circolo e Fondazione Macchi - Oncologia Medica
S.C. EMATOLOGIA
S.C. Gastroenterology and Digestive Endoscopy
S.C. Oncologia
S.C. Oncologia Medica
S.C. Pediatrics, Pediatric Auxology, Endocrinology and Diabetology Clinic
SC di Ematologia
SC Ematologia
SC Endocrinologia, Ospedale di Circolo e Fondazione Macchi, Viale Borri 57, 21100 Varese
SC Medicina Generale
SC Oncologia
SC Oncologia Medica
Struttura Complessa Nefrologia e Dialisi
U.O. di Oncologia Medica
U.O.C Ematologia
Unità di Medicina e Patologia Orale SC Odontostomatologia
UOC Ematologia

Clinical trials at this site (72)

Search interface

An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting

2025-521416-19-00 Recurrence of Clostridioides difficile Infection 4 2026-03-12
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease Recruiting

2024-514110-12-00 Thyroid Eye Disease 7 2025-10-22
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to investigate the efficacy, safety, and pharmacokinetics of oral rilzabrutinib compared with placebo in participants 18 years of ag… Recruiting

2024-517972-39-00 Autoimmune haemolytic anaemia 5 2025-08-19
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Chronic Phase Chronic Myeloid Leukemia 5 2025-04-16
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting

2024-519310-31-00 Anemia due to MDS with del5q with IPSS-R very low, low, 4 2025-01-27
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
AGNOSTIC THERAPY IN A PHASE II, MULTICENTER, SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB (MEDI 4736) IN ASSOCIATION WITH CARBOPLA… Recruiting

2023-505078-13-00 EXTENSIVE STAGE ‐ EXTRAPULMONARY SMALL CELL CARCINOMA 4 2024-01-16
Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy… Recruiting

2023-509793-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 4 2023-11-24
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting

2022-502597-16-00 Intermediate or High-risk Primary or Secondary Myelofib 9 2023-10-27
Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with … Recruiting

2024-514687-33-00 Previously Untreated Chronic Lymphophatic Leukaemia 4 2021-12-21
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting

2024-517200-10-00 Advanced non-small-cell lung cancer 4 2020-01-31